Development of leading first-generation vaccines against SARS-CoV-2

SARS-CoV-2 has infected more than 167 million individuals globally. Highly effective and safe vaccines are required to accelerate the development of herd immunity to end the pandemic. This review focuses on vaccines that are being developed at unprecedented speed globally and are completing late pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Perera, Pin-Yu, Perera, Liyanage P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133830/
https://www.ncbi.nlm.nih.gov/pubmed/34022375
http://dx.doi.org/10.1016/j.micinf.2021.104841
Descripción
Sumario:SARS-CoV-2 has infected more than 167 million individuals globally. Highly effective and safe vaccines are required to accelerate the development of herd immunity to end the pandemic. This review focuses on vaccines that are being developed at unprecedented speed globally and are completing late phase clinical trials to meet this urgent need.

Ejemplares similares